e-learning
resources
Vienna 2012
Monday, 03.09.2012
Treatment of asthma, bronchiectasis and cough: inhaler use
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers
A. Kirsten, O. Holz, R. Tal-Singer, H. Magnussen, H. Watz (Grosshandorf, Hanover, Germany; King of Prussia, United States Of America)
Source:
Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Session:
Treatment of asthma, bronchiectasis and cough: inhaler use
Session type:
Thematic Poster Session
Number:
2170
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Kirsten, O. Holz, R. Tal-Singer, H. Magnussen, H. Watz (Grosshandorf, Hanover, Germany; King of Prussia, United States Of America). The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers. Eur Respir J 2012; 40: Suppl. 56, 2170
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure
Source: Eur Respir J 2005; 25: 797-803
Year: 2005
Ceramide-1-phosphate decreases allergic airway inflammation, remodeling and hyperresponsiveness by inhibition of phosphorilation of NF-kappa B, Akt, MAPK p-38 in dendritic cells
Source: Annual Congress 2010 - Models of airways disease
Year: 2010
Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids
Source: Eur Respir J 2011; 37: 933-942
Year: 2011
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
p38 MAPK inhibitors in COPD
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018
Exposure to LPS induces the upregulation of p38 MAPK in human bronchial epithelium
in vivo
Source: Eur Respir J 2003; 22: Suppl. 45, 459s
Year: 2003
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells.
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021
Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD
Source: Annual Congress 2007 - Epithelial networks in the airways
Year: 2007
p38 MAP kinase mediates apoptosis related to ventilator associated lung injury
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma
Source: Eur Respir J 2010; 35: 750-756
Year: 2010
Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs
Source: Eur Respir J 2013; 42: 28-41
Year: 2013
N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells
Source: Eur Respir J 2003; 22: 43-49
Year: 2003
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019
P38 MAPK and MMP-9 mediate airway mucus hypersecretion induced by acrolein
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation
Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017
Year: 2017
Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009
Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling
Source: Eur Respir J 2005; 26: Suppl. 49, 713s
Year: 2005
Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept